CN118591540A - 包含环状2-氨基-3-氰基噻吩的kras降解化合物 - Google Patents

包含环状2-氨基-3-氰基噻吩的kras降解化合物 Download PDF

Info

Publication number
CN118591540A
CN118591540A CN202280089389.4A CN202280089389A CN118591540A CN 118591540 A CN118591540 A CN 118591540A CN 202280089389 A CN202280089389 A CN 202280089389A CN 118591540 A CN118591540 A CN 118591540A
Authority
CN
China
Prior art keywords
compound
formula
alkyl
kras
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280089389.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·布勒克
A·西尤利
E·迪尔斯
A·戈尔纳
J·古德温-廷德尔
W·法纳比
C·科芬克
A·曼图利迪斯
R·姆克伦南
J·波波夫
M·施米德尔
C·A·P·斯姆瑟斯特
N·特雷纳
H·魏因斯塔布尔
S·钟
D·佐尔曼
J·艾布特
崔剑文
S·W·菲西克
A·利特尔
D·萨尔卡
A·瓦特森
T·霍奇斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Vanderbilt University
Original Assignee
Boehringer Ingelheim International GmbH
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Vanderbilt University filed Critical Boehringer Ingelheim International GmbH
Publication of CN118591540A publication Critical patent/CN118591540A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280089389.4A 2021-12-01 2022-11-30 包含环状2-氨基-3-氰基噻吩的kras降解化合物 Pending CN118591540A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284751P 2021-12-01 2021-12-01
US63/284,751 2021-12-01
PCT/EP2022/083950 WO2023099620A1 (en) 2021-12-01 2022-11-30 Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes

Publications (1)

Publication Number Publication Date
CN118591540A true CN118591540A (zh) 2024-09-03

Family

ID=84537055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280089389.4A Pending CN118591540A (zh) 2021-12-01 2022-11-30 包含环状2-氨基-3-氰基噻吩的kras降解化合物

Country Status (5)

Country Link
US (1) US20250145608A1 (https=)
EP (1) EP4441051A1 (https=)
JP (1) JP2024542692A (https=)
CN (1) CN118591540A (https=)
WO (1) WO2023099620A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
JP7808058B2 (ja) 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
WO2023099624A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
CA3247639A1 (en) 2022-05-06 2023-11-09 PAQ Therapeutics Inc. CHIMERAS TARGET KRAS-G12D PROTEOLYSIS
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
US12448399B2 (en) 2023-01-26 2025-10-21 Arvinas Operations, Inc. Cereblon-based KRAS degrading PROTACs and uses related thereto
KR20260041941A (ko) 2023-03-15 2026-03-27 콴타 테라퓨틱스, 인크. Kras 조절 인자 및 이의 용도
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025016899A1 (en) 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
WO2025026903A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft Imidazo pyrimidine compounds for the treatment of cancer
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN121941690A (zh) 2023-10-03 2026-04-28 Paq医疗公司 Kras蛋白水解靶向嵌合体
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
AU2024361909A1 (en) 2023-10-20 2026-03-26 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
NZ629432A (en) 2012-03-14 2017-01-27 Lupin Ltd Heterocyclyl compounds as mek inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
RS59111B1 (sr) 2014-08-21 2019-09-30 Boehringer Ingelheim Int Nova jedinjenja spiro[3h-indol-3,2´-pirolidin]-2(1h)-ona i derivati kao mdm2-p53 inhibitori
KR20240158360A (ko) 2015-10-09 2024-11-04 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018172250A1 (en) 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2018204532A1 (en) 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
HRP20230400T1 (hr) 2017-12-21 2023-06-23 Boehringer Ingelheim International Gmbh Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US20220274979A1 (en) 2018-04-18 2022-09-01 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
PT3886991T (pt) * 2019-12-11 2022-10-17 Lilly Co Eli Inibidores de kras g12c
UY39129A (es) 2020-03-16 2021-10-29 Novartis Ag Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CN115803030A (zh) * 2020-04-06 2023-03-14 阿维纳斯企业公司 用于kras靶向降解的化合物和方法
WO2021222138A1 (en) * 2020-04-27 2021-11-04 Development Center For Biotechnology Compounds for mutant ras protein degradation
JP7808058B2 (ja) * 2020-06-02 2026-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体

Also Published As

Publication number Publication date
EP4441051A1 (en) 2024-10-09
WO2023099620A1 (en) 2023-06-08
US20250145608A1 (en) 2025-05-08
JP2024542692A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
CN118591540A (zh) 包含环状2-氨基-3-氰基噻吩的kras降解化合物
EP4157837B1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN115485277B (zh) 作为HER2抑制剂的[1,3]二嗪基[5,4-d]嘧啶
JP7626773B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP7626774B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
EP4441050A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN118647620A (zh) 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
CN119841847A (zh) 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
JP2024543982A (ja) がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
EP4441054A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP3728254A1 (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
WO2024246114A1 (en) Survivin as a biomarker for predicting the responsiveness of cancer treatment
HK40097417A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
EA047617B1 (ru) [1,3]ДИАЗИНО[5,4-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ HER2
HK40039222A (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
HK40039222B (en) Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination